The trial will enroll patients with CXCR4-mutated Waldenström’s macroglobulinemia and study the safety and tolerability of mavorixafor and ibrutinib.
Researchers at BostonGene and Weill Cornell Medicine hope their approach may provide a more complete and precise characterization of diffuse large B-cell lymphomas.
Kura Oncology said that it intends to enroll more patients for a registration-directed Phase II trial in 2020 following positive FDA feedback.
The companies will use Freenome's platform to identify cancer patients who are most likely to respond to treatment with ADC's loncastuximab tesirine.
In a Phase II trial, Sophia will look for genomic markers of clinical response to ADC's treatment for relapsed or refractory diffuse large B-cell lymphoma.
CEO Troy Wilson unveiled the first data on tipifarnib demonstrating that biomarkers in the CXCL12 pathway identify which peripheral T-cell lymphoma patients respond best.